UNSPSC 51371908: Acetylmethadol hydrochloride

This classification denotes the hydrochloride form of an opioid receptor agonist with the molecular formula C23H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L59OC40KWJ, chemically known as 6-(dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester) but more generally known as acetylmethadol, which bears US NIH Compound Identifier 10517. Acetylmethadol comes in forms base and hydrochloride.

UNSPSC 51371908 Acetylmethadol hydrochloride is a Commodity code that shows little relevant recent activity. The three recent opportunities tagged to this code—a county naloxone and drug deactivation systems procurement, a state pharmacy benefit RFI, and a multistate generic pharmaceutical cooperative—do not align with acetylmethadol hydrochloride specifically. Acetylmethadol is a synthetic opioid used in maintenance treatment of opioid use disorder, but the recent solicitations address naloxone (an opioid antagonist), direct-to-manufacturer prescription fulfillment models, and generic multi-source pharmaceuticals broadly. The code classification appears to be a tagging mismatch rather than a reflection of actual state and local purchasing patterns for acetylmethadol as a named product.

The issuing bodies in the recent-opportunities block span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota MMCAP serving participating states including Oregon). Geographic activity centers on Florida, Texas, and the MMCAP footprint. No direct procurements for acetylmethadol hydrochloride as a line item appear in these recent records. If this code is intended to track opioid-agonist medications for medication-assisted treatment programs, the code's activity would be better reflected in narrower pharmaceutical manufacturer or wholesale distributor data not present in the state and local opportunity set shown here. Firms pursuing work in opioid-use-disorder treatment procurement should monitor higher-tier pharmaceutical codes and watch for direct RFPs from state health departments and Medicaid agencies rather than relying on this specific commodity code.